PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Neurol Neurosurg Psychiatry. 1991 May; 54(5): 388–396.
PMCID: PMC488535

Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.

Abstract

In six control subjects pars compacta nerve cells in the ventrolateral substantia nigra had a lower melanin content than nerve cells in the dorsomedial region. This coincides with a natural anatomical division into ventral and dorsal tiers, which represent functionally distinct populations. In six cases of Parkinson's disease (PD) the ventral tier showed very few surviving nerve cells compared with preservation of cells in the dorsal tier. In 13 subjects without PD, but with nigral Lewy bodies and cell loss, the degenerative process started in the ventral tier, and spread to the dorsal tier. This pattern of selective degeneration of nigrostriatal neurons is not seen in ageing or after acute administration of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Mann DM, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev. 1983 Feb;21(2):193–203. [PubMed]
  • D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature. 327(6120):324–326. [PubMed]
  • Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745–752. [PMC free article] [PubMed]
  • Braak H, Braak E. Nuclear configuration and neuronal types of the nucleus niger in the brain of the human adult. Hum Neurobiol. 1986;5(2):71–82. [PubMed]
  • Mann DM, Yates PO. Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain. 1974 Sep;97(3):489–498. [PubMed]
  • Spence AM, Gilles FH. Underpigmentation of the substantia nigra in chronic disease in children. Neurology. 1971 Apr;21(4):386–390. [PubMed]
  • GREENFIELD JG, BOSANQUET FD. The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry. 1953 Nov;16(4):213–226. [PMC free article] [PubMed]
  • Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. [PubMed]
  • Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988 Jul 28;334(6180):345–348. [PubMed]
  • McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol. 1977 Jan;34(1):33–35. [PubMed]
  • Mann DM, Yates PO. Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol. 1983 Jan-Feb;9(1):3–19. [PubMed]
  • Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol. 1989 Oct;26(4):551–557. [PubMed]
  • Szabo J. Organization of the ascending striatal afferents in monkeys. J Comp Neurol. 1980 Jan 15;189(2):307–321. [PubMed]
  • Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988 Apr 7;318(14):876–880. [PubMed]
  • Snyder SH, D'Amato RJ. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology. 1986 Feb;36(2):250–258. [PubMed]
  • D'Amato RJ, Lipman ZP, Snyder SH. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science. 1986 Feb 28;231(4741):987–989. [PubMed]
  • Pifl C, Schingnitz G, Hornykiewicz O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett. 1988 Oct 5;92(2):228–233. [PubMed]
  • Bédard P, Larochelle L, Parent A, Poirier LJ. The nigrostriatal pathway: a correlative study based on neuroanatomical and neurochemical criteria in the cat and the monkey. Exp Neurol. 1969 Nov;25(3):365–377. [PubMed]
  • Carpenter MB, Peter P. Nigrostriatal and nigrothalamic fibers in the rhesus monkey. J Comp Neurol. 1972 Jan;144(1):93–115. [PubMed]
  • Fallon JH, Moore RY. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol. 1978 Aug 1;180(3):545–580. [PubMed]
  • Gerfen CR. The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat. J Comp Neurol. 1985 Jun 22;236(4):454–476. [PubMed]
  • Smith Y, Parent A. Differential connections of caudate nucleus and putamen in the squirrel monkey (Saimiri sciureus). Neuroscience. 1986 Jun;18(2):347–371. [PubMed]
  • Jimenez-Castellanos J, Graybiel AM. Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix. Neuroscience. 1987 Oct;23(1):223–242. [PubMed]
  • Herkenham M, Edley SM, Stuart J. Cell clusters in the nucleus accumbens of the rat, and the mosaic relationship of opiate receptors, acetylcholinesterase and subcortical afferent terminations. Neuroscience. 1984 Mar;11(3):561–593. [PubMed]
  • Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci. 1987 Dec;7(12):3915–3934. [PubMed]
  • Langer LF, Graybiel AM. Distinct nigrostriatal projection systems innervate striosomes and matrix in the primate striatum. Brain Res. 1989 Oct 2;498(2):344–350. [PubMed]
  • Gerfen CR, Baimbridge KG, Thibault J. The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J Neurosci. 1987 Dec;7(12):3935–3944. [PubMed]
  • Graybiel AM, Moratalla R. Dopamine uptake sites in the striatum are distributed differentially in striosome and matrix compartments. Proc Natl Acad Sci U S A. 1989 Nov;86(22):9020–9024. [PubMed]
  • Turner BH, Wilson JS, McKenzie JC, Richtand N. MPTP produces a pattern of nigrostriatal degeneration which coincides with the mosaic organization of the caudate nucleus. Brain Res. 1988 Nov 8;473(1):60–64. [PubMed]
  • Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, LHeureux R, Hauw JJ, Duyckaerts C, Gray F, Morel-Maroger A, Rascol A, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol. 1985 Nov;18(5):523–529. [PubMed]
  • ADAMS RD, VANBOGAERT L, VANDEREECKEN H. STRIATO-NIGRAL DEGENERATION. J Neuropathol Exp Neurol. 1964 Oct;23:584–608. [PubMed]
  • Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain. 1990 Dec;113(Pt 6):1823–1842. [PubMed]
  • Spokes EG, Bannister R, Oppenheimer DR. Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases. J Neurol Sci. 1979 Sep;43(1):59–82. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group